Mega Lifesciences PCL (BKK:MEGA)
Thailand · Delayed Price · Currency is THB | Market Cap | 29.64B +12.4% |
| Revenue (ttm) | 14.40B -1.6% |
| Net Income | 2.07B +4.1% |
| EPS | 2.37 +3.8% |
| Shares Out | 871.87M |
| PE Ratio | 14.37 |
| Forward PE | 12.55 |
| Dividend | 1.60 (4.71%) |
| Ex-Dividend Date | Mar 9, 2026 |
| Volume | 2,457,089 |
| Open | 34.25 |
| Previous Close | 34.25 |
| Day's Range | 33.75 - 34.75 |
| 52-Week Range | 24.60 - 40.00 |
| Beta | 0.32 |
| Analysts | Buy |
| Price Target | 41.14 (+21.0%) |
| Earnings Date | Aug 13, 2026 |
About Mega Lifesciences PCL
Mega Lifesciences Public Company Limited, together with its subsidiaries, manufactures and sells health food supplements, prescription pharmaceutical products, over-the-counter products, herbal products, vitamins, and fast-moving consumer goods. The company operates through three segments: Brands, Distribution, and Original Equipment Manufacture. It offers wellness and nutrition products, including medical and sports nutrition, general well-being, vitamins, probiotics, herbal medicines, and cough and cold medicines, as well as hair, kid’s, men’... [Read more]
Financial Performance
In 2025, Mega Lifesciences PCL's revenue was 14.19 billion, a decrease of -7.74% compared to the previous year's 15.39 billion. Earnings were 1.91 billion, a decrease of -4.99%.
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for MEGA stock is "Buy." The 12-month stock price target is ฿41.14, which is an increase of 21.00% from the latest price.
News
Mega Lifesciences PCL Earnings Call Transcript: Q1 2026
Q1 2026 saw 14.4% revenue growth, strong Branded business performance, and margin expansion, with net profit up 34% YoY. Guidance for 8%-12% Branded and 8%-10% Distribution growth is maintained, supported by robust volume-driven demand and ongoing manufacturing investments.
Mega Lifesciences PCL Quarterly report: Q1 2026
Mega Lifesciences PCL has published its Q1 2026 quarterly earnings report on May 14, 2026.
Mega Lifesciences PCL Earnings Call Transcript: Q4 2025
FY 2025 saw revenue decline narrow to 7.8% YoY, with branded business growing 4.3% and distribution recovering in 2H. Gross margin improved, and EBITDA rose 2.6% YoY. FY 2026 revenue is guided to grow 8-12%, led by branded business and Myanmar recovery.
Mega Lifesciences PCL Quarterly report: Q4 2025
Mega Lifesciences PCL has published its Q4 2025 quarterly earnings report on February 25, 2026.
Mega Lifesciences PCL Slides: Q4 2025
Mega Lifesciences PCL has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on February 25, 2026.
Mega Lifesciences PCL Earnings Call Transcript: Q3 2025
Nine-month 2025 revenue reached THB 10.4 billion, with branded business growing 4.3% YoY and distribution stabilizing. Q3 net profit rose 29.1% YoY, and the company expects low double-digit branded growth and stable dividends, while investing in new manufacturing facilities.
Mega Lifesciences PCL Quarterly report: Q3 2025
Mega Lifesciences PCL has published its Q3 2025 quarterly earnings report on November 14, 2025.
Mega Lifesciences PCL Slides: Q3 2025
Mega Lifesciences PCL has posted slides in relation to its Q3 2025 quarterly earnings report, which was published on November 14, 2025.
Mega Lifesciences PCL Earnings Call Transcript: Q2 2025
Strategic focus on brand and product development is supported by a five-year growth plan, with higher second-half revenue and stable profitability expected. CapEx is concentrated in Indonesia and Vietnam, and internal cash flow is projected to cover investments and debt.
Mega Lifesciences PCL Quarterly report: Q2 2025
Mega Lifesciences PCL has published its Q2 2025 quarterly earnings report on August 28, 2025.
Mega Lifesciences PCL Slides: Q2 2025
Mega Lifesciences PCL has posted slides in relation to its Q2 2025 quarterly earnings report, which was published on August 28, 2025.